Pharma and biotech executives lead program at ChinaBio® Partnering Forum 2013 in Beijing
The fifth annual ChinaBio®Partnering Forum will bring executives from pharmaceutical companies including Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Merck, Novo Nordisk and Sanofi; and leading venture capital firms such as TusPark Ventures, Qiming Venture Partners, Lilly Asia Ventures, OrbiMed Asia and others to Beijing this May 29–30.
The 2013 keynote, “Partnering landscape in China: Joining the global game,” will examine the trends and factors driving cross-border partnering in China, and the potential changes coming in the next few years, as China becomes the number two global pharma market. The keynote panel of global pharma and China company executives will be moderated by Greg B. Scott, President and Founder of ChinaBio® LLC and features executive panelists Eckhard Ottow, Head of Global Innovation Sourcing, Global Drug Discovery, Bayer Pharma AG; May Wang, Senior VP, Head of Business Development and Strategic Alliances, Hutchison MediPharma;Greg Wiederrecht, VP and Head, External Scientific Affairs, Worldwide Licensing and Acquisitions, Merck Research Laboratories; and Steve Yang, VP, Head of Asia and Emerging Markets iMed, AstraZeneca.
“China is a growth market for new research facilities that focus on innovative drugs. There are many talented scientists and institutions in China that can bring valuable contributions to address the healthcare challenges of today and those of the future. This is why AstraZeneca continues to seek out opportunities to collaborate with best-in-class academic and medical institutions here,” said Yang. “China has put huge investment into drug development pipelines in recent years and this will be a focus of the keynote panel discussion.”
Another program highlight will be the plenary panel “Biosimilars and biologics in China: The race is on” that will focus on the rapidly changing world of biologics and biosimilars, and China’s potential to be a global leader in the sector despite ongoing regulatory challenges. Executive panelists include Chris Chen, Senior VP of Biologics, WuXi AppTec; Hans-Peter Grau, VP of Business Development and Key Account Management Asia, Boehringer Ingelheim; Michael Yu, President and CEO, Innovent Biologics Inc.; and Joe Zhou, CEO, Genor BioPharma Ltd., Wison Group.
“There are many distinct challenges in developing and manufacturing biologics to meet global regulatory standards and patients’ needs,” said Grau. “Such challenges are no less present in China, but there are changes on the horizon that could make China the new destination market for developing these drugs. The panel should prove an interesting discussion about how China proposes to overcome existing challenges and hurdles to lead biologic/biosimilar drug development.”
“Development and manufacturing of products in China is the new strategy for many MNCs, as once again the imported products–specifically biologics–are not able to compete,” said Yu. “In fact, domestically made biologics have much better market performance than imported products in the same category, I think this will lead to many new cross-border partnerships.”
The overall program will focus on global partnering in China, and features industry executives from leading Chinese companies and global pharma speaking on topics ranging from AIA post-grant proceedings and VC investment in China, to deconstructing the deal. In addition, the Partnering Forum will include over 30 company presentations, and two days of panels, workshops and networking opportunities.
“There is huge demand in China for Western partnerships that will bring innovative drugs to China’s aging population,” said Carola Schropp, President of EBD Group. “Partnership opportunities in China are attractive to pharma companies and investors, and ChinaBio®Partnering Forum is the place where they can find their ideal potential partners to capitalize on this growing market.”
EBD Group, the premier partnering conference firm for the life science industry, and ChinaBio® LLC, a leading consulting firm in Shanghai, announced that the fifth annual event, to be held at the Shangri-La Hotel Beijing, is expected to bring over 800 life science dealmakers to China. The 2012 forum was attended by 719 delegates from 402 companies and 23 countries who engaged in more than 1100 one-to-one meetings facilitated by partneringONE®. Sixty-three percent of attending companies in 2012 were from China.
For information on how to register, go towww.ebdgroup.com/cbpf/registration/index.php.
ChinaBio® Partnering Forum is the premier life science partnering event in China. The annual event attracts biotech and pharma leaders from around the world and engages delegates with one-to-one meetings, workshops and panels, exhibits and networking receptions and a gala banquet evening event. For more information, please go to www.ebdgroup.com/cbpf.
About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® LLC
- EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
- The Global Impact Forum™, a unique and innovative partnering conference in impact investing and venture philanthropy.
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
About ChinaBio® LLC
Since its founding in January, 2007, ChinaBio® LLC has rapidly created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped global life science companies identify over 400 licensing and acquisition opportunities in China and China companies raise over USD 450 million.
- Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees.
- Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy.
- Capital: ChinaBio helps companies secure partnerships and acquisitions and access private and government funding in China.
- Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry, with over 18,000 readers.
More information is available at www.chinabiollc.com
EBD Group, Inc.
2032 Corte del Nogal, Suite 120
Carlsbad, CA 92011 USA
+1 760 930 0500
780 Cailun Road, #822
Shanghai 201203 China
From China: +86 21 5137 0751 ext 20
From USA: +1 858 926 4566 ext 12